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Abstract  
 
Background 
Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a rare, Non-Hodgkin 
lymphoma arising in the capsule of breast implants. BIA-ALCL presents as a recurrent effusion 
and/or mass. Tumours exhibit CD30 expression and are negative for anaplastic lymphoma kinase 
(ALK). We report the multi-disciplinary management of the UK series and how the stage of 
disease may be used to stratify treatment.  
 
Methods  
Between 2012 and 2016, 23 cases of BIA-ALCL were diagnosed in 15 regional centres throughout 
the UK. Data on breast implant surgeries, clinical features, treatment and follow-up were 
available for 18 patients.  
 
Results 
The mean lead-time from initial implant insertion to diagnosis was 10 years (range: 3-16). All 
cases were observed in patients with textured breast implants or expanders. Fifteen patients 
with breast implants presented with stage I disease (capsule confined), and were treated with 
implant removal and capsulectomy. One patient received adjuvant chest-wall radiotherapy. 
Three patients presented with extra-capsular masses (stage IIA). In addition to explantation, 
capsulectomy and excision of the mass, all patients received neo-/adjuvant chemotherapy with 
CHOP as first line. One patient progressed on CHOP but achieved pathological complete response 
(pCR) with Brentuximab Vedotin. After a mean follow-up of 23 months (range: 1-56) all patients 
reported here remain disease-free.  
 
Discussion 
BIA-ALCL is a rare neoplasm with a good prognosis. Our data support the recommendation that 
stage I disease be managed with surgery alone. Adjuvant chemotherapy may be required for 
more invasive disease and our experience has shown the efficacy of Brentuximab as a second line 
treatment.  
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Introduction 
Breast implant associated anaplastic large cell lymphoma (BIA-ALCL) is an extremely rare, Non-
Hodgkin lymphoma of T-cell origin. This association was highlighted by the Food and Drug 
Administration in the United States in 2011 (1, 2) and, whilst breast implants have been in use 
since 1962, the first case was only reported in 1997 (3). Since then, whether through increased 
use of implants, or growing clinician awareness and acceptance of this rare complication, the rate 
of diagnosis is rising: the largest published case series reports 173 cases (4, 5).  De Jong and 
colleagues estimate an incidence of BIA-ALCL of 1-3 cases in 1 million breast implant cases per 
year (6) however opinion in some other countries express possible higher risks (7) and more 
robust epidemiological studies are required.  
 
The aetiology of this disease remains unclear and, despite the growing body of evidence 
implicating chronic inflammation within the capsular biofilm, some authors advise caution in 
drawing conclusions until science catches up with this unusual entity (8, 9). In the modern era of 
breast augmentation and reconstruction the proportion of textured implants used greatly 
exceeds the number of smooth shell devices and this may partly explain why almost all cases 
have arisen in association with textured implants. It is not clear if this is the whole story and one 
working theory is that, when compared with smooth implants, concavities present from the 
macro-texturing process predispose to sub-clinical infection and/or to chronic inflammatory 
stimulation (10). Honghua et al have recently reported an increased prevalence of certain gram-
negative organisms (Ralstonia spp) within the microbiome of implant capsules taken from 
patients with BIA-ALCL compared to controls. The notion that a pro-inflammatory environment 
can precede cancerous change is not a new one; the very rare association of Helicobacter pylori 
infection and gastric lymphoma is already well documented (11, 12).  
 
  
Presentation of the disease 
 
Women who develop BIA-ALCL typically present with either large volume peri-implant effusions 
(80%) or solid capsule-related masses (20%)(13). Many benign causes for the sudden 
development of fluid around the implant exist and these will vastly outnumber those due to BIA-
ALCL (14) . Diagnosis is made by the finding of abnormal cells in the aspirate or biopsy 
accompanied by the hallmark uniform over-expression of CD30 and negative staining for 
Anaplastic Lymphoma Kinase (ALK) (5, 15-17). 
 
As proposed by Clemens et al, stage I disease remains confined to the effusion or a layer on the 
luminal side of the capsule, whereas stage II (and above) disease presents with extra-capsular 
spread, regional nodal or distant metastases (18). Whether these two presentations are indeed 
distinct disease entities or whether they are at opposing ends of a disease spectrum remains 
unknown at present. Patients with stage I disease can be treated adequately with implant 
removal and total capsulectomy. These patients may be at risk of over–treatment with adjuvant 
medical therapies if the indolent natural history of this disease is not fully appreciated.  
 
In patients with stage II disease (locally advanced) and stage III/IV disease (regional and distant 
spread), treatment may involve adjuvant therapies. Standard chemotherapy regimens used in the 
management of systemic ALCL are anthracycline–based, such as cyclophosphamide, doxorubicin, 
vincristine and prednisolone (CHOP). Such regimens appear to be more effective in patients with 
ALK-positive systemic ALCL when compared to ALK-negative disease (5-year survival rates of 
70-90% Vs. 40-60%). In patients with ALK negative systemic disease CHOP may be ineffective. 
Other regimens may be used and remissions consolidated with autologous stem cell 
transplantation (19). In BIA-ALCL (characteristically ALK-negative on immunohistochemistry), 
CHOP regimens have been reported for adjuvant treatment – however, their efficacy remains to 
be proven in the first line. In six reported cases of death secondary to BIA-ALCL, two thirds of 
patients receiving CHOP progressed through treatment (18). Clinical trials assessing the use of 
Brentuximab Vedotin, a monoclonal anti-CD30 antibody conjugated to the anti-microtubule 
agent monomethyl auristatin E, for the treatment of relapsed, refractory ALCL may have a 
specific role in ALK-negative systemic disease and BIA-ALCL. Trials have reported response rates 
of 86% and complete remission rates of 59% in ALK-negative tumours (20, 21). Brentuximab 
Vedotin appears to be well tolerated and patient-reported outcomes appear to show significant 
improvements in quality of life after commencing this therapy compared to other agents (22). It 
is noteworthy that none of the six reported patients that died from BIA-ALCL received 
Brentuximab Vedotin (18) but if a similar response is seen in BIA-ALCL, it may herald a paradigm 
shift in the treatment of advanced BIA-ALCL.  
 
It is mandatory that all confirmed cases in the United Kingdom are reported to the MHRA 
(Medicines and Healthcare Products Regulatory Agency), or the equivalent medical regulatory 
authority if outside. The Plastic Surgery Foundation, based in the United States of America, in 
collaboration with the American Society of Plastic Surgeons (ASPS) and the Food and Drug 
Administration (FDA), have created a BIA-ALCL-specific database for collecting and following up 
all cases of BIA-ALCL worldwide and after patient consent we strongly recommend confirmed 
cases be included in this registry (23). The PROFILE registry also provides up to date information 
on BIA-ALCL. 
  
Patients and Methods 
 
In total, 23 cases of BIA-ALCL have been diagnosed and within the UK to date. Through close 
collaboration between the Association of Breast Surgery (ABS), British Association of Plastic, 
Reconstructive and Aesthetic Surgeons (BAPRAS) and the British Association of Aesthetic Plastic 
Surgeons (BAAPS) networks we gathered information about cases of BIA-ALCL within the UK 
population. We report a case series of 18 patients diagnosed with BIA-ALCL between 2012 and 
2016 across 15 regional centres. One of the patients has already been presented as a case report 
in the literature (24) and an earlier summary of UK cases diagnosed to date was presented at the 
San Antonio Breast Cancer Conference 2016 (25). Table 1 summarises the details of each case.  
  
Results 
The mean age at diagnosis was 52 years (range 29-73 years) and the mean lead-time from 
implant placement to diagnosis was 10 years (range 3-16 years). Indications for implant use 
were breast augmentation (56%), breast reconstruction following mastectomy for breast cancer 
(33%) and reconstruction following mastectomy for risk reduction (11%). Seven patients who 
presented with a recurrent, large-volume effusion were diagnosed with BIA-ALCL between 1 and 
3 years after their initial symptomatic presentation with effusion. Six of the seven patients had 
capsule-confined disease (stage I) at eventual diagnosis. In two of these cases, a retrospective 
review of the earlier cytopathology from previous symptomatic presentations suggested the 
presence of BIA-ALCL in previous aspiration samples.  They came to no harm and remain well 
and disease-free. One patient, who is discussed in more detail later, appeared to have seeding of 
BIA-ALCL from the capsule to the site of the surgical drain after capsulectomy and implant 
exchange for a problematic effusion not thought to be secondary to BIA-ALCL at the time of 
surgery.  
 
Ten patients had the diagnosis of BIA-ALCL made pre-operatively. This was accomplished by fine 
needle aspiration (FNA) of effusion fluid (N=5), needle core biopsy (NCB) of the presenting mass 
(N=3), capsule biopsy alone (N=1) and, in one case, a combination of capsule biopsy and FNAC 
was required. Three patients had the diagnosis made following surgery: one patient had a 
capsulectomy and implant replacement with a micro polyurethane textured device for recurrent 
effusion; one had exchange of implant and seroma drainage for change in shape for an assumed 
ruptured implant (which was intact at surgery), the other was diagnosed following review of 
cytology from the drained effusion.   
  
 Stage I disease  
 
All patients were managed through a multidisciplinary team with specialist haemato-oncology 
opinion. Using current BIA-ALCL staging, 15 patients had Stage I disease and presented with a 
recurrent, large volume effusion. They were treated successfully with implant removal and total 
capsulectomy and have a mean follow up of 21 months to February 2017. The indications for 
implant insertion were: bilateral breast augmentation (BBA) (N=7), bilateral risk-reducing 
mastectomy (RRM) with immediate breast reconstruction (N=2), mastectomy for cancer with 
immediate breast reconstruction (N=4) and mastectomy with delayed breast reconstruction 
(N=2). Of this latter group, one patient was reconstructed using tissue expansion and the second 
underwent implant assisted Latissimus Dorsi (LD) flap reconstruction. Two patients with stage I 
disease had received prior breast cancer related adjuvant chemotherapy, chest wall radiotherapy 
and endocrine therapy with Tamoxifen. 
 
Seven patients diagnosed with BIA-ALCL still had their initial implants in situ at the time of 
diagnosis of BIA-ALCL. Of the remainder, six had undergone tissue expander (TE) insertion at 
primary reconstruction of which five had undergone exchange for a fixed-volume implant and 
one had undergone exchange to an identical tissue expander prior to developing BIA-ALCL. The 
remaining two patients had previous fixed volume implants exchanged for replacement implants 
on at least one occasion prior to diagnosis of BIA-ALCL. 
 
In total, eight patients had at least one other device implanted before the current in situ device. 
The details of the device was unknown in one patient. 
 
 
  
Stage II disease  
 
Three patients presented with stage IIA disease. One patient, who had undergone previous BBA 
with subsequent exchange of implants and capsulectomies, presented with a mass two months 
following surgery and had BIA-ALCL confirmed on biopsy. She was entered into the ECHELON 2 
trial (CHOP v. Brentuximab Vedotin + CHOP). Her treatment remains blinded within the confines 
of the trial – however, she achieved a complete clinical and radiological (PET-CT) response and 
was treated with further adjuvant radiotherapy to her chest wall.  
 
The second patient with stage II disease had previously undergone BBA with subsequent implant 
exchange and bilateral capsulectomies (performed overseas four months prior to presentation) 
and then developed a mass at the surgical drain site. Biopsy of the mass confirmed BIA-ALCL. We 
postulate this represents cutaneous seeding to the drain site from undiagnosed BIA-ALCL at the 
time of implant exchange and strengthens the argument for complete en bloc capsulectomy with 
the implant. Unfortunately, there is no capsule available for retrospective pathological 
examination in this case. She underwent wide local excision of this mass with adjuvant CHOP 
chemotherapy and radiotherapy and to date, remains well with no evidence of recurrence at 4 
years post-treatment. 
 
The third patient with stage II disease had previously undergone BBA and presented with an 
isolated mass adjacent to the implant on the anterior chest wall, which was confirmed as BIA-
ALCL on biopsy.  She underwent three cycles of CHOP chemotherapy and progressed rapidly 
during treatment to develop life threatening chest wall/thoracic cavity involvement (figure 2 a 
and c). It was unclear whether resection would be feasible, so a trial of neoadjuvant Brentuximab 
Vedotin was commenced. She achieved complete clinical and radiological response following six 
cycles (figure 2 b-e) and underwent bilateral total capsulectomy and implant removal, which 
confirmed a pathological complete response (pCR).  
 
All patients have been followed-up to date with PET-CT and all remain disease free with the 
treatment as discussed. 
Discussion 
 
We show that BIA-ALCL is a diagnosed entity in the UK with 44% of patients having implants for 
reconstruction and the remainder having primary breast augmentation (56%). This differs only 
marginally from the previous published series when 60% of cases of ALCL were seen following 
BBA and the remaining 40% seen in reconstruction patients (5). More importantly there does not 
appear to be clustering of cases to a specific surgeon or unit or geographical location suggesting 
that local factors do not affect the development of BIA-ALCL.  
 
Delays in diagnosis in seven (39%) patients in this series are probably due to the lack of 
awareness of BIA-ALCL in women, breast radiologists, pathologist, breast and plastic surgeons. 
Work has started to raise awareness amongst women (26) and UK professionals alike  (27, 28). 
 
Systemic ALCL (non-BIA associated) is a rare and aggressive lymphoma with poor outcomes 
requiring extensive systemic treatment and is traditionally staged using the Ann Arbour 
classification which may risk over-staging and thus over-treating the more localised BIA-ALCL. 
The newer BIA-ALCL specific staging system proposed by Clemens et al recognises a very low 
risk group with localised intra-luminal disease and a separate higher risk group with extra-
luminal disease or a breast mass who will benefit from more aggressive systemic treatment (29). 
The UK data support this classification. 
 
Stage I BIA-ALCL presenting as a sudden, late effusion is on the whole an indolent disease. Seven 
patients in this series had symptomatic effusions some time prior to final diagnosis of BIA-ALCL 
and six but did not have disease progression during that time. One patient in whom there was a 
delay in diagnosis appeared to progress by seeding of cells following implant exchange into 
adjacent normal tissue (thus up-staging the disease). This highlights the importance of complete 
capsulectomy with en bloc excision of the capsule and effusion during surgery if BIA-ALCL is 
either already diagnosed or clinically suspected.  
 
Stage II BIA-ALCL presents as either an extra-capsular mass (T4M0N0) or has lymphoma cells 
infiltrating the capsule with nodal metastasis (T1-3N1M0) and appears to behave in a more 
aggressive manner. Our experiences in managing such stage II BIA-ALCL cases resonate with 
global opinion that these patients appear to benefit the most from adjuvant therapies. 
Specifically, in our series, we report for the first time the use of Brentuximab Vedotin in the 
neoadjuvant setting for BIA-ALCL in a patient who progressed on first line CHOP. She 
demonstrated a complete clinical, radiological and pathological response (figure 2). Whilst it is 
not possible to speculate on the details of randomisation for the patient entered into ECHELON 2, 
we look forward to the maturation of this trial data as they may change the current standard of 
care for ALK-negative ALCL – and BIA-ALCL in particular – significantly. 
 
In addition, the risk of developing recurrent, or a new primary, BIA-ALCL tumour if the affected 
textured implant is exchanged with a new device remains uncertain. Whether the textured 
implant should be replaced with another textured device, or perhaps a smooth one, also remains 
unclear.  Pragmatically speaking, removing the ipsilateral implant alone in a patient with 
bilateral implants will result in profound asymmetry, so decisions regarding immediate bilateral 
implant replacement or bilateral implant removal to maintain symmetry is for discussion 
between the surgeon and the patient and should be judged on a case-by-case basis however 
oncological safety should always come before aesthetic considerations.  A consensus group 
consulted on these questions were unable to reach a conclusion due to the dearth of clinical and 
biological information about this disease (30).  
 
The National Comprehensive Cancer Network in the United States has developed an algorithm 
for the management of BIA-ALCL (33). Healthcare provision and funding differs in the UK so we 
propose a modified algorithm for the management of suspected BIA-ALCL specific for the UK 
health system outlining the requirements for a histological diagnosis and the principles of 
management (figure 3). 
 
 
BIA-ALCL is a rare condition that presents with a sudden onset effusion around an implant; it is 
usually curable by total capsuelctomy. Our paper describing the current UK case reports, 
management and outcomes is part of a wider strategy to raise awareness through education and 
better information.  It is recommended that cases are managed in specialist tertiary centres 
which have the appropriate experience and expertise in the management of BIA-ALCL. We feel 
that this will permit consolidation of clinical and research resources and will lead to a better 
understanding of lymphomagenesis in this context.  
 
  
 BIA-ALCL and the breast implant registry 
We can only get more complete data prospectively through national observational studies and 
BIA-ALCL highlights the relevance and importance of the recently launched Breast and Cosmetic 
Implant Registry (BCIR) and consenting all patients for inclusion in the registry (31). This 
national database will help in building up an accurate picture on implant usage and the 
consequent monitoring and collation of long-term sequelae. 
 
BIA-ALCL and consent 
One of the broader issues related to BIA-ALCL pertains to patient consent. The occurrence of BIA-
ALCL highlights the importance of surgeons consenting patients for inclusion in the implant 
registry (31). A recent, informal conference poll of plastic surgeons in the UK suggested that 75% 
of respondents did not routinely discuss BIA-ALCL with their patients prior to implant surgery 
(29). The reasoning for this is unclear – but is likely to stem from a lack of information about, and 
appreciation of, the disease entity by the surgical world. We can be reassured that the discussion 
of BIA-ALCL with patients preparing for implant surgery appears to have no deleterious effect on 
the treatment plan, as patients still undergo implant surgery after being fully informed (29). 
 
Following the recent Montgomery ruling in 2015 in the UK (32), the GMC’s Guide to Good Medical 
Practice (which favours a patient-centred approach to consent) is no longer considered a guide, 
but is now a mandatory requirement. This stance must be reflected in our decision to discuss 
BIA-ALCL with patients. 
 
In response to the High Court Judgement in the case of Montgomery ‘v’ Lanarkshire Health Board, 
the GMC stated that “risk shouldn’t be a numbers game, it should be part of dialogue”. “A material 
risk is one that a reasonable person in the patient’s position is likely to apply significance to”. In 
the BIA-ALCL context, although the risk is extremely low, it is nevertheless our duty to inform 
any patient receiving a breast implant that there is a risk. 
 
The published literature unanimously agrees that BIA-ALCL is a distinct entity and that a failure 
to inform patients of this risk is a failure in your duty to the patient (18, 29), exposes the surgeon 
to potential litigation and is significantly at odds with the GMC guidelines on Good Medical 
Practice. 
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